News & Updates

Dietary nitrate supplementation for patients with chronic obstructive pulmonary disease (COPD) appears to lead to better exercise capacity, according to a study.

Adding clarithromycin to standard of care appears to improve clinical response and reduce inflammation in patients with community-acquired pneumonia, as reported in the phase III ACCESS trial.

Treatment with tiotropium appears to reduce the risk of clinically important deterioration (CID) in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), including those with fewer respiratory symptoms, according to a study.

Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.